论文部分内容阅读
来自于日本干叶大学医学研究生院的Takayuki Kawata博士及其同事在近期出版的《美国心脏学杂志》(AHJ)上刊文报道说,血管紧张素转化酶(ACE)抑制剂可改善2型糖尿病患者的冠状动脉血流速度储备(CFVR),但血管紧张素Ⅱ-1型受体拮抗剂candesartan(坎地沙坦)并不影响CFVR。 Kawata博士等人指出,现已有证据显示这两种类型的药物均对糖尿病患者有利;紧急输注ACE抑制剂可增加糖尿病患者的冠脉灌注,但究竟两类药物对糖尿病患者的冠脉循环的效应是否相似尚不清楚。
Takayuki Kawata, MD, from Nagoya Medical University, Japan, and colleagues report in a recent issue of the American Journal of Cardiology (AHJ) that angiotensin-converting enzyme (ACE) inhibitors can improve type 2 diabetes Patients with coronary artery flow velocity reserve (CFVR), but the candesartan (candesartan), an angiotensin II-1 receptor antagonist, did not affect CFVR. Kawata et al. Have pointed out that there is now evidence that both types of drugs are beneficial for patients with diabetes; emergency infusion of ACE inhibitors can increase coronary perfusion in diabetic patients, but whether the two types of drugs on coronary artery disease in patients with coronary artery disease Whether the effect is similar is not clear.